UBS Group set a €85.00 ($100.00) price objective on Bayer (FRA:BAYN) in a report published on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other brokerages have also recently issued reports on BAYN. JPMorgan Chase & Co. set a €77.00 ($90.59) price objective on shares of Bayer and gave the company a neutral rating in a research note on Wednesday, October 21st. Baader Bank set a €105.00 ($123.53) price target on shares of Bayer and gave the stock a buy rating in a research note on Tuesday, August 4th. Barclays set a €50.00 ($58.82) price target on shares of Bayer and gave the stock a neutral rating in a research note on Tuesday, October 13th. DZ Bank reiterated a buy rating on shares of Bayer in a research note on Monday, August 24th. Finally, Independent Research set a €48.00 ($56.47) price objective on shares of Bayer and gave the company a neutral rating in a research report on Friday, October 2nd. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Bayer currently has an average rating of Buy and an average price target of €73.38 ($86.32).
BAYN stock opened at €40.79 ($47.98) on Monday. Bayer has a one year low of €91.58 ($107.74) and a one year high of €123.82 ($145.67). The firm has a 50 day simple moving average of €49.42 and a two-hundred day simple moving average of €57.81.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Further Reading: What is a recession?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.